Search clinical trials for: Plerixafor Dose Escalation

Total 6645 results

Sidney Kimmel Comprehensive Cancer Center at Johns...
StemlineTherapeutics, Inc.

Recruiting

Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML (GO-TAG)

Acute Myeloid Leukemia

United States
Rigshospitalet, Denmark
Hvidovre University Hospital

Recruiting

Individualized Antibiotic Therapy in Children With Acute Uncomplicated Febrile Urinary Tract Infection

Febrile Urinary Tract Infection

Denmark
Mingzhi Zhang

Recruiting

A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma

China
Mayo Clinic

Completed

Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma

United States
Anand Jillella
Novartis Pharmaceuticals

Completed

Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL) (BUS48T)

Mantle Cell Lymphoma

United States
Basilea Pharmaceutica

Completed

Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

Fungal Infection

Netherlands
Rajiv Gandhi Cancer Institute & Research Center...
Varian, a Siemens Healthineers Company

Recruiting

Dose Escalation Using Hypoxia-adjusted Radiotherapy (DE-HyART)

Head and Neck Squamous Cell Carcinoma

India
Makerere University
University of Liverpool

Completed

Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis

HIV Infections | Tuberculosis

Uganda
Region Skane
Exact Sciences Corporation

Recruiting

The T-REX Trial: Tailored Regional External Beam Radiotherapy in Clinically Node-negative Breast Cancer Patients With 1-2 Sentinel Node Macrometastases. (T-REX)

Breast Cancer

Sweden
Brii Biosciences Limited

Completed

A Study of BRII-297 in Healthy Adult Subjects

Postpartum Depression

Australia
Hospital Universitario Dr. Jose E. Gonzalez

Unknown

Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation

Lymphoma, Non-Hodgkin | Myeloma | Lymphoma, Hodgkin | Stem Cell Transplant Complications

Mexico
University Health Network, Toronto
Princess Margaret Hospital, Canada

Completed

Feasibility and Efficiency Study of Leukemic Cell Mobilization With Plerixafor Injection

Acute Myeloid Leukemia

Canada
Genzyme, a Sanofi Company

Completed

Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients

Lymphoma, Non-Hodgkin | Multiple Myeloma

United States
Genzyme, a Sanofi Company
AnorMED

Completed

Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

Lymphoma, Non-Hodgkin | Multiple Myeloma

Germany
AVEM HealthCare

Not yet recruiting

The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19 (ARDOXSO)

Covid19 | Acute Respiratory Distress Syndrome | Novel Coronavirus Pneumonia

United States
Yong Chen

Not yet recruiting

The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma

Melanoma Stage III

China
Roswell Park Cancer Institute
National Cancer Institute (NCI); GlaxoSmithKline

Terminated

Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia

Waldenström Macroglobulinemia

United States
Genzyme, a Sanofi Company

Approved for marketing

Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization (CUP)

Autologous Stem Cell Transplant
University of Liverpool
Genzyme, a Sanofi Company

Unknown

Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC) (PHANTASTIC)

Lymphoma | Lymphoproliferative Disorders | Multiple Myeloma | Plasma Cell Dyscrasia

United Kingdom
Ahon Pharmaceutical Co., Ltd.
Zhejiang Cancer Hospital; Fudan University; Sir Run Run Shaw Hospital

Unknown

Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c

Breast Neoplasms

China
Chinook Therapeutics, Inc.

Active, not recruiting

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

IgA Nephropathy

Korea, Republic of, United States, United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD (CARSAF)

Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
Suzhou Alphamab Co., Ltd.

Recruiting

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia

Hemophilia

China
Pluristem Ltd.

Completed

Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)

Intermittent Claudication | Peripheral Artery Disease

United States, Germany, Korea, Republic of, Israel
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG1837

Healthy

Belgium
University of Zurich

Recruiting

Dose Escalation for SBRT of Recurrent VT Ventricular Tachyarrhythmia - a Single Center, Phase II Clinical Trial (DEFT STAR)

Ventricular Tachycardia

Switzerland
Peking Union Medical College Hospital

Not yet recruiting

Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP

Thrombotic Thrombocytopenic Purpura, Acquired

China
TyrNovo Ltd.

Active, not recruiting

A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer

Head and Neck Cancer | Squamous Cell Carcinoma of Head and Neck | Metastatic Solid Tumor | Colorectal Adenocarcinoma | Solid Tumor, Adult | Recurrent Solid Tumor

United States, Israel
Fondazione Policlinico Universitario Agostino Gemelli...
Viewray Inc.

Unknown

THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy (THUNDER2)

Locally Advanced Rectal Cancer | Pathological Complete Response | Neoadjuvant Chemoradiotherapy

Italy
Universitaire Ziekenhuizen KU Leuven
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer (Everest2)

Colorectal Cancer

Spain, France, Belgium, Hungary, Austria
Peking Union Medical College Hospital

Unknown

Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A

Acquired Hemophilia A

China
Genzyme, a Sanofi Company

Completed

AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF

Lymphoma, Non-Hodgkin | Multiple Myeloma

Canada
1ST Biotherapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

Advanced Solid Tumor

United States
University of Minnesota

Recruiting

Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients

Solid Organ Transplant

United States
Hospital Universitari Vall d'Hebron Research Institute
CIEMAT; CIBERER

Completed

Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1

Fanconi Anemia

Spain
Genzyme, a Sanofi Company

Completed

A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). (PREDICT)

Transplantation | Lymphoma (Non-Hodgkin's Lymphoma) | Hodgkin's Disease or Multiple Myeloma | Front Line Mobilization

Netherlands, France, Germany, Sweden, Spain, Italy, United Kingdom
Genzyme, a Sanofi Company

Completed

A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent

Healthy Volunteer

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Completed

Prospective Observational Study on Plerixafor After Chemotherapy

Lymphoma | Myeloma

Italy
British Columbia Cancer Agency

Completed

Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype Early Stage Endometrial Cancer (TAPER)

Endometrial Cancer

Canada
Chinese University of Hong Kong

Recruiting

EUS-FNB With MOSE vs EUS-FNA With ROSE (MORE)

Pancreatic Neoplasms

Hong Kong
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
Genzyme, a Sanofi Company
AnorMED

Terminated

Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation

Multiple Myeloma

United States
Dana-Farber Cancer Institute
Millennium Pharmaceuticals, Inc.

Completed

Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)

Waldenstrom's Macroglobulinemia

United States
Ludwig-Maximilians - University of Munich

Recruiting

Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma (PRIDE)

Glioblastoma

Germany
Astex Pharmaceuticals, Inc.

Completed

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome | MDS

United States, Canada
Genzyme, a Sanofi Company

Completed

AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts

Autologous Stem Cell Transplantation

United States
Damascus University

Completed

Effect of Laser Application in Pain Management Following the Use of Orthodontic Elastomeric Separators

Orthodontic Treatment

Syrian Arab Republic
Genzyme, a Sanofi Company

Completed

Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma

Multiple Myeloma

Japan
EpicentRx, Inc.

Completed

RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1)

Glioblastoma | Oligodendroglioma | Anaplastic Oligodendroglioma

United States
King Faisal Specialist Hospital & Research Centre...

Withdrawn

Can we Transfuse Blood Over Shorter Period ?

Blood Transfusion Complication

3

Subscribe